Webcast scheduled for Friday, May 31 at 8:00
a.m. Eastern Time
CARLSBAD, Calif., May 28, 2024
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
announced today that it will host a live webcast on Friday, May 31th at 8:00 a.m. Eastern Time to discuss the
donidalorsen Phase 3 OASIS-HAE and OASISplus (Open-Label Extension
and Switch cohorts) study results that will be presented in three
late-breaking oral presentations at the 2024 European Academy of
Allergy and Clinical Immunology (EAACI) Annual Meeting in
Valencia, Spain.
The webcast may be accessed at
https://ir.ionispharma.com/events-and-presentations/upcoming-events.
A replay will be available for a limited time at the same
address.
About Ionis Pharmaceuticals, Inc.
For three decades,
Ionis has invented medicines that bring better futures to people
with serious diseases. Ionis currently has five marketed medicines
and a leading pipeline in neurology, cardiology, and other areas of
high patient need. As the pioneer in RNA-targeted medicines, Ionis
continues to drive innovation in RNA therapies in addition to
advancing new approaches in gene editing. A deep understanding of
disease biology and industry-leading technology propels our work,
coupled with a passion and urgency to deliver life-changing
advances for patients. To learn more about Ionis, visit
Ionispharma.com and follow us on X (Twitter) and LinkedIn.
Ionis Pharmaceuticals Investor Contact:
D.
Wade Walke, Ph.D. –
info@ionisph.com – 760-603-2331
Ionis Pharmaceuticals Media Contact:
Hayley Soffer –
CorporateCommunications@ionisph.com – 760-603-4679
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ionis-to-hold-donidalorsen-phase-3-data-webcast-302156276.html
SOURCE Ionis Pharmaceuticals, Inc.